ADMA Biologics

ADMA Biologics is an American biopharmaceutical and specialty immunoglobulin company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. ADMA Biologics was founded in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Biologics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

ADMA Biologics balance sheet

Report period2018 2019 2020 2021 2022Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

ADMA Biologics cash flows

Report period2018 2019 2020 2021 2022Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

ADMA Biologics multipliers

Report period2018 2019 2020 2021 2022Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

ADMA Biologics profitability

Report period2018 2019 2020 2021 2022Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
ADMA Biologics assets
ADMA Biologics cash flows

ADMA Biologics dividend policy

The company doesn't provide dividend

ADMA Biologics shares

TickerNameTypeNominal valueISINPrice
ADMA:USADMA BiologicsCommon share-US00768Y8185$22.62
ADMA Biologics news
12.05.2022
ADMA Biologics' GAAP loss for 3 months of 2022 was $25.008 million, up 36.1% from $18.38 million in the prior year. Revenue increased 81.3% to $29.103 million from $16.049 million a year earlier.
Source: {source} pictogram admabiologics.com
Pictogram next
25.03.2022
ADMA Biologics' GAAP loss for 2021 was $71.648 million, down 5.4% from $75.749 million in the previous year. Revenue increased 91.7% to $80.943 million from $42.22 million a year earlier.
Source: {source} pictogram admabiologics.com
Pictogram next
11.11.2021
ADMA Biologics' GAAP loss for 9M 2021 was $54.998 million, down 2.4% from $56.34 million in the prior year. Revenue increased 93% to $54.56 million from $28.263 million a year earlier.
Source: {source} pictogram admabiologics.com
Pictogram next
08.09.2021
ADMA Biologics has received FDA approval for its VanRx SA25 machine. It is designed for automatic packaging of both injectable and lyophilized drug forms, and is also capable of quickly switching between different container and closure formats.
Source: {source} pictogram admabiologics.com
Pictogram next
All ADMA Biologics news
General information
Company nameADMA Biologics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address465 Route 17 South Ramsey, NJ 07446 United States
Mailing address465 Route 17 South Ramsey, NJ 07446 United States
Websitewww.admabiologics.com
Information disclosurewww.sec.gov